Related Experiment Video
Updated: Jul 6, 2026
09:35
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
[Advance in technical method and treatment for viral hepatitis]
1Department of Hepatology, Toranomon Hospital, Kawasaki.
Rinsho Byori. the Japanese Journal of Clinical Pathology
|April 12, 2008
Summary
Nucleic acid analogs like entecavir are preferred for hepatitis B treatment due to low mutation rates, unlike interferon
Area of Science:
- Hepatology
- Virology
- Internal Medicine
Background:
- Current hepatitis B treatment involves interferon or nucleic acid analogs.
- Nucleic acid analogs are primary treatments due to interferon's low response rate (~30%).
- Entecavir exhibits the lowest mutant emergence rate (~3% over 3 years) among nucleic acid analogs.
Purpose of the Study:
- To review current treatment strategies for hepatitis B and C.
- To highlight the efficacy and limitations of different antiviral therapies.
- To discuss the role of interferon and its combinations in hepatitis C management.
Main Methods:
- Review of existing literature on hepatitis B and C treatment protocols.
- Analysis of response rates and mutant emergence associated with various therapies.
- Comparison of treatment outcomes based on viral load, genotype, and drug resistance.
Main Results:
- Nucleic acid analogs, particularly entecavir, are favored for hepatitis B due to low resistance.
- Hepatitis C treatment combines interferon plus ribavirin, with varying response rates by genotype.
- Interferon monotherapy shows a 70% response rate in low viral load cases, regardless of genotype.
Conclusions:
- Entecavir is a key therapy for hepatitis B, minimizing drug resistance.
- Combination therapy and interferon monotherapy are tailored for hepatitis C based on viral load and genotype.
- Beta-interferon plays a role in preventing cancer in cirrhotic patients.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:28Viral Hepatitis I: Introduction
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...